- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03179319
Mobile-Based Application "MyChoices"
Mobile-Based Application "MyChoices" to Increase Uptake of HIV Testing, Detection of New HIV Infections, and Linkage to Care and Prevention Services by Young Men Who Have Sex With Men
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
"MyChoices", an app adapted from HealthMindr and developed using iterative feedback from youth, is being refined to to maximize acceptability among YMSM. "MyChoices" was guided by the Social Cognitive Theory (SCT) model and includes three major functions that are designed to promote self-efficacy, self-regulation, goal-setting and environmental influences in order to impact behavior change. (1) Tracking and Self-Monitoring HIV Risk: In order to target self-regulation, brief surveys within the app are used to assess behavioral patterns of YMSM, particularly around sexual relationships, which are then used to help customize the app for each user. (2) HIV and sexually transmitted infection (STI) Prevention Information: In order to improve self-efficacy for HIV testing and HIV prevention overall, quizzes and infographics that appeal to YMSM have been incorporated into the app, focusing on promotion of HIV prevention and regular HIV testing. The app also allows users to order OraQuick HIV home testing kits and STI home collection kits (for rectal and urethral gonorrhea and Chlamydia and syphilis). Additionally, the app includes information on testing sites and local PrEP clinics (e.g., telephone, address, hours of testing, etc), and external links to specific site webpages that are near the user (determined using GPS technology). (3) HIV Testing Plan: Acknowledging the central role of goal setting and environmental influences on health behavior, the app allows users to create a HIV testing plan by allowing them to compare and choose different screening options (e.g., home self-testing, antigen, rapid). Questions about HIV transmission behaviors and testing history are then asked to create a tailored testing plan. After a HIV testing plan is developed, users have the option to customize reminders for the timeframe selected (e.g., user is pinged every 3 months as a reminder to get tested). Users are able to select from a list of phrases or create their own to ensure privacy. Moreover, geofencing technology allows users to be notified when in the vicinity of testing locations, based on the Geo Positioning System (GPS) location, during the testing timeframe.
This study is part of the iTech NIH U19, which has an overall goal to develop innovative technology-focused interventions addressing the HIV prevention and care continuum for youth.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Fenway Health Center
-
-
New York
-
Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- No HIV test in the past 3 months (self-reported).
- Not known to be HIV-infected (self-reported).
- Not currently taking PrEP (self-report).
- Owns or leases a phone with Android platform (for Aims 2 and 3) or iOS platform (Aim 3 only), has an active data plan, and willing to download the MyChoices application.
- Willing to attend an in-person baseline study visit in Boston or the Bronx and complete online follow-up visits.
- Able to understand, read, and speak English.
- Participants ages 15-18: self-report at least one episode of anal intercourse with a male or transfemale partner during the last 6 months.
Participants ages 19-24: self-report evidence of high risk for acquiring HIV infection including at least one of the following:
- at least one episode of condomless anal intercourse with an HIV-infected or unknown HIV status male or transfemale partner during the last 6 months; or
- anal intercourse with 2 or more male or transfemale sex partners during the last 6 months; or
- exchange of money, gifts, shelter, or drugs for anal sex with a male or transfemale partner during the last 6 months; or
- sex with a male or transfemale partner and has had an STI during the last 6 months.
Exclusion Criteria:
- Any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions.
- Prior enrollment in an HIV vaccine trial with receipt of experimental vaccine product and evidence of vaccine-induced seropositivity.
- Known to be HIV-infected.
- Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: MyChoices
Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
|
Acesso ao aplicativo móvel MyChoices, que inclui o plano de teste de HIV com lembretes, informações sobre IST, recursos de PrEP, links para sites de teste e PrEP e recursos de geolocalização.
|
|
Sem intervenção: Standard of Care
Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Acceptability: System Usability Scale
Prazo: 3 months
|
System Usability Scale: a validated scale that assesses subjective usability of a system, or, in this case, an app.
The System Usability Scale consists of a 10 item questionnaire with five response options; from Strongly agree to Strongly disagree.
The items scores are converted into a score from 0 (negative) to 100 (positive).
A score of ≥50 indicates that the app is acceptable, and a score above 68 is considered above average.
|
3 months
|
|
Feasibility: Frequency of Logins
Prazo: 3 months
|
Number of individuals who logged into app at least one time after set up
|
3 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Preliminary Efficacy: Number of Participants Self-reported Having Tested for HIV
Prazo: 6 months
|
Self-report having tested for HIV over follow up
|
6 months
|
|
Preliminary Efficacy: Number of Participants Self-reported Having Initiated PrEP
Prazo: 6 months
|
Self-report of participants reporting PrEP initiation anytime over study follow up
|
6 months
|
|
Number of Times Participants Used Distinct App Components
Prazo: 3 months
|
The total number of times that participants selected distinct components (e.g., testing plan, ordering, FAQs) of the app were summed
|
3 months
|
|
App Content and Functionality Most Utilized
Prazo: 3 months
|
We a priori identified the primary app components (i.e., HIV test plan, location search, ordering supplies, FAQs) and report the number of participants using these app components at least once over follow up
|
3 months
|
|
Number of HIV Home Testing Kits Ordered
Prazo: 6 months
|
Number of Participants who ordered at least one HIV home testing kit over follow up
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Katie B Biello, PhD, MPH, Protocol Co-Chair, Research Study MPI
- Investigador principal: Kenneth H Mayer, MD, Fenway Health Center
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1U19HD089881 (SubProject 8784)
- 1U19HD089881 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .